The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Survival Analysis for Breast Cancer Patients with Different Times of Diagnosis of First Metastases.
 
Jaffer A. Ajani
Honoraria - Bayer; Five Prime Therapeutics; Genentech; Lilly/ImClone; Novartis; Roche/Genentech; Taiho Pharmaceutical
Research Funding - Amgen; Bristol-Myers Squibb; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; MedImmune; Merck; Novartis; Roche/Genentech; Taiho Pharmaceutical; Takeda
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly
Travel, Accommodations, Expenses - Bayer; Five Prime Therapeutics; Novartis
 
Ken Kato
Consulting or Advisory Role - Ono Pharmaceutical
Research Funding - MSD Oncology; Ono Pharmaceutical; Shionogi
 
Yuichiro Doki
No Relationships to Disclose
 
Ian Chau
Honoraria - Amgen; Gilead Sciences; Lilly; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; MSD Oncology; Roche/Genentech; Sanofi
Research Funding - Janssen-Cilag (Inst); Lilly (Inst); Merck Serono (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck Serono; MSD; Sanofi
 
Ioannis Xynos
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
 
Agnes Balogh
Employment - Bristol-Myers Squibb
Stock and Other Ownership Interests - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Yuko Kitagawa
Honoraria - Chugai Pharma; Ethicon; Nippon Kayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ajinomoto (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); GlaxoSmithKline (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kureha (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Medtronic (Inst); Merck Serono (Inst); Nippon Kayaku (Inst); Novartis (Inst); Otsuka (Inst); Otsuka (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Taisho Toyama Pharma (Inst); Takeda (Inst); Teijin Pharma (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)